TP53 and cancer: To determine the transcriptomic differences driving this aggressive phenotype in Trp53;Nf2 codeleted cancers when compared with individual Trp53 or Nf2 deleted tumors, we undertook bulk RNA-seq of tumors with KrasG12D;Trp53KO, KrasG12D;Nf2KO or KrasG12D;Trp53KO;Nf2KO genetic profiles.